Sex and Gender Differences in Acute Care Neurology
Women experience worse stroke outcomes than men, including greater disability, higher rates of nursing home admission, and more mental impairment even after adjusting for age, and they present with distinct symptom patterns that require heightened clinical awareness to avoid misdiagnosis. 1
Stroke: Presentation and Outcomes
Key Epidemiological Differences
Women develop stroke at older ages than men, but age alone does not explain the outcome disparities 1. Even after age adjustment, women have significantly poorer outcomes including greater pre- and post-stroke disability, higher likelihood of nursing facility admission, and greater mental impairments 1.
Symptom Presentation Patterns
Women present more frequently with nonfocal symptoms that may lead to misdiagnosis:
- Headache (24% increased odds) 2
- Altered consciousness/mental status changes (38% increased odds) 2
- Coma/stupor (39% increased odds) 2
- Dysarthria (14% increased odds) 2
- Vertigo (23% increased odds) 2
Women present less frequently with:
This atypical presentation pattern creates a critical pitfall: the absence of classic focal deficits in women may delay recognition and treatment 2.
Stroke Severity and Type
When women do have ischemic stroke, they present with higher stroke severity scores and more frequently have proximal large vessel occlusions 3. Despite this, women actually receive reperfusion therapy more frequently (48.2% vs 43.1% in men) 3, suggesting that once recognized, treatment access is appropriate.
Treatment Disparities
In-hospital care shows persistent sex-based delays:
- Door-to-needle time is 4-8 minutes longer in women 4
- Women are less likely to be admitted to stroke units (OR 0.89) 5
- Women undergo MRI less frequently (OR 0.85) 5
- Women receive echocardiography less frequently (OR 0.85) 5
However, these disparities appear to be in-hospital system issues rather than differences in treatment eligibility, as women have comparable rates of thrombolysis and endovascular treatment once the diagnosis is made 3, 4.
Outcomes and Mortality
Women have worse 90-day outcomes, particularly after intravenous thrombolysis alone (good outcome: 56.7% vs 63.8% in men) 3. However, this difference disappears in patients receiving mechanical thrombectomy, and sex itself is not independently associated with poor outcome when adjusted for age and stroke severity 3.
Paradoxically, men have higher all-cause mortality and higher rates of recurrent stroke-related readmission during follow-up 5.
Stroke Prevention: Unique Female Risk Factors
Hormone-Related Risks
Women have stroke risk factors that are entirely unique to their sex:
Postmenopausal hormone therapy increases ischemic stroke risk (RR 1.44 for combined estrogen/progestin; RR 1.39 for estrogen alone) based on Women's Health Initiative data 1. This represents a critical clinical decision point: hormone therapy should not be used for stroke prevention and increases stroke risk 1.
Aspirin for Primary Prevention
Sex-specific responses to aspirin exist: Women aged ≥45 years at low cardiovascular risk showed stroke reduction with low-dose aspirin in the Women's Health Study, while men in the Physician's Health Study showed no stroke benefit 1. However, these studies were conducted at different time periods, limiting direct comparison.
Migraine
Epidemiology
Migraine disproportionately affects women: 21% of women vs 11% of men in the United States 6. Migraine ranks as the top cause of global disability in women aged 15-49 years 6.
Sex vs Gender Effects
Recent longitudinal data demonstrates that sex (biological) has the strongest effect on migraine incidence (3.1 times higher in females: 6.2% vs 2.0%), while gender (social/behavioral factors) shows no direct effect on migraine 7. This suggests migraine differences are primarily biological rather than socially mediated.
Treatment Considerations
The 2025 ACP guideline for acute migraine treatment does not differentiate recommendations by sex, recommending triptans added to NSAIDs for moderate-to-severe migraine in nonpregnant adults 6. The "nonpregnant" specification is critical, as triptans have pregnancy considerations.
Alzheimer's Disease
While mentioned in the overview paper 8, the provided evidence does not contain specific data on sex/gender differences in Alzheimer's presentation or treatment. The evidence acknowledges this as an area requiring attention but lacks detail.
Clinical Recommendations for Practice
For Stroke Recognition:
- Maintain high suspicion in women presenting with atypical symptoms (headache, altered mental status, vertigo without clear focal deficits)
- Do not require classic hemiparesis or focal visual symptoms to activate stroke protocols in women
- Recognize that women with stroke are typically older and have higher baseline disability
For Stroke Treatment:
- Expedite door-to-needle times in women through system-level interventions to eliminate the 4-8 minute delay
- Ensure equal access to stroke unit care and diagnostic imaging (MRI, echocardiography)
- Consider mechanical thrombectomy aggressively as it eliminates sex-based outcome disparities seen with thrombolysis alone
For Stroke Prevention:
- Avoid hormone therapy for stroke prevention - it increases risk
- Consider low-dose aspirin for primary prevention in women ≥45 years at low cardiovascular risk
- Screen for female-specific risk factors (pregnancy history, oral contraceptive use, hormone therapy)
For Migraine:
- Recognize the 3-fold higher incidence in women as primarily biological
- Use standard treatment algorithms (triptans + NSAIDs) without sex-based modification in nonpregnant adults
The evidence demonstrates that while biological sex creates fundamental differences in stroke and migraine epidemiology, many observed disparities in stroke care represent modifiable system-level delays rather than appropriate clinical differentiation 8, 4, 5.